Hexarelin Peptide: The Synthetic Growth Hormone Analog

The synthetic GH analog, Hexarelin, has been the subject of many research studies yielding promising properties. Some of those studies will be mentioned in this article, along with Hexarelin’s main functions when used in clinical investigations by licensed professionals. 

Studies suggest that when tested on animals, Hexarelin may be useful in promoting joint repair, protection, healing, neural protection, increased muscle fiber size, and increased strength.

Studies speculate that the peptide may potentially reduce total adipose tissue, which may further aid in weight loss. Hormonal changes alone account for visible growth since these changes neither hasten stomach emptying nor increase hunger.

Experts suggest the pituitary gland secretes growth hormones (GH), a crucial hormone in male and female test subjects. Organisms rely on growth hormones for several key functions, including normal metabolism, muscle growth, cell regeneration, skin thickness, and general well-being.

Studies speculate that a lack of growth hormones may negatively affect overall health. A drop in hormone levels like this is frequent in adult subjects, older research models, and those with an underlying growth hormone shortage. The question then becomes how to counteract the normal decline in growth hormone levels.

What is Hexarelin?

Studies suggest that Hexarelin is a GHRP with structural similarities with another potentially peptide, GHRP-6 [i]. Hexarelin is a peptide-based synthetic compound of six amino acids. [ii]

According to theoretical research, the naturally occurring human hormone ghrelin releases a peptide chain of 28 amino acids called “growth hormone”. Studies suggest Hexarelin may be one of the many synthetic substances that mimic ghrelin action developed over the last 25 years [iii]. Since then, there have been many studies and investigations into the properties of peptides.

Hexarelin Mechanism of Action

In order to determine how Hexarelin works, research [iv] was performed using both young and mature rats. The natural growth hormone-releasing hormone (GHRH) was immunized passively from birth in this study’s 10-day-old pups. These puppies received Hexarelin twice daily for 3-10 days. The results suggested that the subjects’ plasma growth hormone levels were significantly elevated after the peptide was presented. In addition, the anterior pituitary tissue was surgically removed from adult male rats. (i.e., mediobasal hypothalamus removal.)

Five days before surgery, these rats were given Hexarelin in preparation. The growth hormone levels did not seem to alter much with this. Interestingly, GHRH allegedly elicited substantial levels of growth hormones in these surgically-altered rats within 7 days of presentation. Hexarelin and GHRH may have caused comparable increases in the hormone’s plasma levels after 30 days.

Hexarelin may exhibit several properties, as suggested by research studies:

  • It may raise the growth hormone levels 
  • It may cause gains in lean body mass
  • It may boost the metabolism and cut fat levels
  • It may improve injury healing rates 
  • It may increase muscular strength and bone density
  • It may affect the insulin growth factor 
  • It may amplify hormones associated with ACTH 

Hexarelin Peptide Research Studies

Hexarelin and GH1 Cell Lines

The primary objective of this in vitro [v] investigation was to examine the effects of Hexarelin on the GHRH-insensitive GH1 rat tumor cell line. In addition, the role of GHRH in Hexarelin’s actions on GH1 rat cells was tracked in this work.

Studies suggested that GHRH boosted GH production in healthy rat cells but did not impact the GH1 subtype. Furthermore, GHRH did not appear to affect GH secretion when combined with Hexarelin. Based on these findings, it seems that GHRPs like Hexarelin may be able to operate on cells insensitive to the actions of GHRHs.

Hexarelin and Histamine Release 

Research suggests Hexarelin may result in favorable inotropic effects on the circulatory system [vi]. When given to seven healthy male test subjects, the peptide was reported by researchers to improve the LVEF ejection rate without altering blood pressure. Up to an hour after delivery, this impact was still present. Hexarelin appeared to enhance cardiac output, arterial pressure, and heart rate in 24 male research models with coronary artery disease having surgery under general anesthesia.

Studies speculate that Hexarelin also restored the electrophysiological characteristics of cardiac cells and blocked cell death when given to ischemic rat hearts, resulting in inotropic properties and boosting heart cell survival. [vii]

Experimentally induced myocardial infarction was simulated in male rats. The data suggested that the subject’s peripheral resistance decreased after the peptide was presented, and their stroke volume and cardiac output rose.


The synthetic GHRP, Hexarelin, consists of six amino acids and is structurally comparable to GHRP-6, another well-known peptide. Researchers speculate that Hexarelin’s potential may mitigate the adverse properties of reduced growth hormone levels. Research studies suggest that the release of the stress hormone cortisol rises when Hexarelin is present, leading to possible actions on metabolism, lean body mass, and cardiovascular health.

Only academic and scientific institutions are permitted to use Hexarelin. If you are a researcher interested in purchasing Hexarelin peptides for your clinical studies, you can do so by visiting Core Peptides. Please note that none of the items listed are approved for human or animal consumption. Laboratory research chemicals are only for in-vitro and in-lab use. Any kind of physical introduction is illegal. 


[i] Giustina A, Bonfanti C, Licini M, Ragni G, Stefana B. Hexarelin, a novel GHRP-6 analog, stimulates growth hormone (GH) release in a GH-secreting rat cell line (GH1) insensitive to GH-releasing hormone. Regul Pept. 1997 May 14;70(1):49-54. https://pubmed.ncbi.nlm.nih.gov/9250581/

[ii] National Center for Biotechnology Information (2021). PubChem Compound Summary for CID 6918297, Examorelin. Retrieved August 19, 2021 from https://pubchem.ncbi.nlm.nih.gov/compound/Examorelin

[iii] Fabio Broglio et al, Ghrelin: Much more than a natural growth hormone secretagogue. Division of Endocrinology and Metabolism, Department of Internal Medicine; Division of Pathological Anatomy, Department of Biomedical Sciences and Oncology https://www.ima.org.il/FilesUploadPublic/IMAJ/0/56/28152.pdf

[iv] Torsello A, Grilli R, Luoni M, Guidi M, Ghigo MC, Wehrenberg WB, Deghenghi R, Müller EE, Locatelli V. Mechanism of action of Hexarelin. I. Growth hormone-releasing activity in the rat. Eur J Endocrinol. 1996 Oct;135(4):481-8. https://pubmed.ncbi.nlm.nih.gov/8921832/

[v] Giustina A, Bonfanti C, Licini M, Ragni G, Stefana B. Hexarelin, a novel GHRP-6 analog, stimulates growth hormone (GH) release in a GH-secreting rat cell line (GH1) insensitive to GH-releasing hormone. Regul Pept. 1997 May 14;70(1):49-54. https://pubmed.ncbi.nlm.nih.gov/9250581/

[vi] Mao, Yuanjie et al. “The cardiovascular action of hexarelin.” Journal of geriatric cardiology : JGC vol. 11,3 (2014): 253-8. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4178518/ 

[vii] Ma Y, Zhang L, Edwards JN, Launikonis BS, Chen C. Growth hormone secretagogues protect mouse cardiomyocytes from in vitro ischemia/reperfusion injury through regulation of intracellular calcium. PLoS One. 2012;7(4):e35265. https://pubmed.ncbi.nlm.nih.gov/22493744/



0 comments on “Hexarelin Peptide: The Synthetic Growth Hormone AnalogAdd yours →

Leave a Reply

Your email address will not be published.